Welcome to our dedicated page for Select Medical SEC filings (Ticker: SEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Select Medical Holdings Corporation (NYSE: SEM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a public company operating critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics across many U.S. states, Select Medical uses its SEC filings to report financial results, corporate actions, governance changes, and material events affecting its three reportable segments.
Current and periodic reports. Investors can review Select Medical’s current reports on Form 8-K, which the company uses to announce items such as quarterly and annual financial results, cash dividend declarations, updates to its common stock repurchase program, and significant financing transactions. Recent 8-K filings describe earnings releases for multiple quarters, dividend declarations, amendments to the company’s credit agreement, and the issuance of senior notes used together with term loan proceeds and cash on hand to redeem prior notes and repay existing term loans.
Other 8-K filings detail governance and organizational changes, including the appointment of a new chief executive officer, related board role changes, and an employment agreement with the chief executive officer. The company has also filed an 8-K describing amendments and restatements of its bylaws to address procedural and disclosure requirements for stockholder nominations and proposals in light of universal proxy rules. Another 8-K furnishes a press release acknowledging a non-binding indication of interest from the Executive Chairman, Co-Founder and Director to acquire all outstanding shares of Select Medical for cash consideration within a stated range per share.
Annual and quarterly reporting. While not reproduced in full here, Select Medical’s Form 10-K annual reports and Form 10-Q quarterly reports provide detailed financial statements, segment information for its critical illness recovery hospital, rehabilitation hospital, and outpatient rehabilitation segments, and risk factor discussions. These filings expand on topics referenced in press releases, such as reimbursement risk, labor availability, Medicare certification requirements, competition, and technology and cybersecurity considerations.
Using Stock Titan’s tools. On Stock Titan, Select Medical’s SEC filings are updated in near real time as new documents are posted to EDGAR. AI-powered summaries help explain the key points of lengthy filings, including how segment results relate to the company’s post-acute care operations and what specific corporate or financing actions mean for the capital structure. Users can quickly scan 10-K and 10-Q disclosures, 8-K current reports, and exhibits such as amended bylaws or employment agreements to understand how Select Medical’s regulatory reporting reflects developments in its hospital and outpatient rehabilitation businesses.
Select Medical Holdings (SEM): Executive Vice President John F. Duggan reported a Form 4 transaction on 11/01/2025. He surrendered 4,865 shares of common stock at $13.83 under code F to satisfy tax withholding related to the vesting of restricted stock.
Following this administrative withholding, he directly owns 194,710 shares. This filing reflects a tax-related share withholding rather than an open-market sale.
Select Medical Holdings (SEM)11/01/2025, the CFO executed a Code F transaction, surrendering 7,357 shares of common stock at $13.83 per share to cover tax withholding tied to the vesting of restricted stock.
Following this tax-related withholding, the CFO beneficially owns 238,057 shares on a direct basis. This filing reflects administrative share withholding rather than an open‑market sale.
Select Medical Holdings (SEM) reported an insider equity award. An Executive Vice President acquired 50,000 shares of common stock on 10/28/2025 at $0 per share, recorded as a grant of restricted stock. Following the transaction, the officer beneficially owns 199,575 shares, held directly.
The restricted stock, subject to certain exceptions, will vest in full on 10/28/2029, the fourth anniversary of the grant date.
Select Medical Holdings (SEM) reported an insider equity transaction. A director received 1,266 shares of common stock on 10/28/2025 at a price of $14.22 per share. Following the grant, the reporting person beneficially owned 304,063 shares, held directly.
The filing states this was a restricted stock grant under the 2020 Equity Incentive Plan, issued in lieu of a quarterly cash retainer of $18,000. This reflects routine director compensation in stock rather than cash.
Select Medical Holdings (SEM) reported an insider equity award. The company’s Chief Accounting Officer received a grant of 20,000 shares of restricted stock on 10/28/2025 at $0 per share. According to the terms, the award will vest in full on October 28, 2029. Following the grant, the reporting person beneficially owns 54,254 shares, held directly.
Select Medical Holdings Corporation furnished a press release announcing financial results for the third quarter ended September 30, 2025. The materials were provided under Item 2.02 and are treated as furnished, not filed, under the Exchange Act.
The Board also declared a cash dividend of $0.0625 per share, payable on or about November 25, 2025 to stockholders of record as of the close of business on November 12, 2025. The press release with financial schedules was included as Exhibit 99.1.
Select Medical Holdings (SEM) reported Q3 results with revenue of $1,363,445 thousand, up from $1,271,582 thousand a year ago. Income from continuing operations, net of tax, was $44,180 thousand versus $41,276 thousand, and EPS from continuing operations was $0.23 versus $0.19. Adjusted EBITDA reached $111,655 thousand compared with $103,898 thousand.
By segment, revenue was $609,929 thousand in Critical Illness Recovery Hospitals, $328,607 thousand in Rehabilitation Hospitals, and $325,383 thousand in Outpatient Rehabilitation. For the nine months ended September 30, 2025, revenue was $4,056,196 thousand and income from continuing operations, net of tax, was $176,791 thousand, with EPS from continuing operations of $1.00. Operating cash flow for the period was $282,142 thousand, and capital expenditures were $170,125 thousand. Total debt had a carrying value of $1,772,149 thousand. As of September 30, 2025, SEM had 123,817,591 shares outstanding.
John F. Duggan, Executive Vice President and a director of Select Medical Holdings Corporation (SEM), reported beneficial ownership of 149,575 shares of the issuer's common stock. The filing discloses four grants of restricted stock: three grants of 25,000 shares (granted on November 1 of 2021, 2022 and 2023) and one grant of 50,000 shares (granted April 30, 2024). Each grant includes vesting schedules that generally fully vest on the fourth anniversary of the grant date, with a special one‑third vesting event noted on November 5, 2024, and other customary exceptions.
Select Medical Holdings Corporation (SEM) filed an 8-K reporting leadership changes. The filing references Item 5.02 and Item 7.01 and includes an exhibit: a press release dated September 2, 2025 announcing the appointment of Mr. Mullin as Chief Executive Officer and noting other changes involving long-tenured leaders. The 8-K indicates the company furnished written communications under Regulation FD and provided the press release as Exhibit 99.1. The disclosure signals a formal CEO transition and related leadership adjustments, documented through the company’s required SEC communication channels.